Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
COVID vaccination gives huge boost to post-infection immunity
Fri February 26th - Vaccination is acting as a booster dose for people already enjoying some protection against COVID-19 after exposure to the disease, British scientists reported last night. More
Increased opioid agonist treatment could reduce drug deaths
Fri February 26th - Scaling up the use of opioid agonists could help to reduce drug-related deaths substantially, new international research claims. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Drug-resistant prostate cancer treatment 'promising'

Tuesday January 12th 2021

Men with advanced prostate cancer could receive a promising, new experimental drug, it is reported today.

Scientists at the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, believe the chemical structure of CCS1477, a new targeted drug, could be used to stop the growth of late-stage prostate cancers.

The new research, published in Cancer Discovery, also reveals the drug’s mechanism of action and it is now being evaluated in clinical trials as a monotherapy for patients with prostate cancer, and also in combination with existing drugs such as enzalutamide and abiraterone.

The team studied cell lines and tumour biopsies from 43 patients in the lab and showed that CCS1477 works by binding itself to two cancer gene regulators, the proteins p300 and CBP, which help activate androgen receptor signalling.

By blocking the activity of these two proteins, the drug can stop prostate cancer’s growth and potentially delay or prevent drug resistance.

Compared to those who had lower levels of the p300 protein, participating patients who had higher levels of the p300 protein did not live as long before their cancer progressed and became drug resistant than those with lower levels of the protein – 10 months compared with 21 months.

When researchers blocked the activity of the CBP and p300 genes – either separately or in combination – in cells in the lab, there was less activity in the androgen receptor and c-Myc, and slower growth of prostate cancer cells taken from patients,

This, they say, confirms that targeting those two proteins had an effect on androgen receptor signalling.

Re-activating p300 and CBP in patient samples switched on signalling through the androgen receptor and c-Myc, which helped to fuel the growth of cancer cells.

Using CCS1477 to block p300 and CBP in mice with prostate cancer was found to have a biological effect on androgen receptor signalling and could stop tumour growth.

The report’s authors suggest that CCS1477 can both target androgen receptor signalling and but also the potential genomic changes and adaptations prostate cancer may undergo to evade treatment, which may enable it to be used in combination with modern hormone drugs to overcome or delay resistance to treatment.

CCS1477 is also being trialled in patients with blood cancers and those whose tumours have a range of mutations, including changes in genes such as p300, CBP or c-Myc.

Study leader Professor Johann de Bono, professor of experimental cancer medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said: “Our study offers a potentially exciting new approach to treating prostate cancer. For the first time, we have shown that blocking two proteins known as p300 and CBP with a new targeted drug can disrupt signals that help fuel the growth of prostate cancers.

“These initial results are very promising and suggest that the drug could help delay or prevent resistance to the modern hormone treatments abiraterone and enzalutamide, which have already played a critical role in helping patients to live for much longer.”

Study author Dr Adam Sharp, team leader in translational therapeutics at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: “Being able to target both androgen receptor signalling and its adaptions is a huge achievement, as it helps us tackle the huge challenge posed by cancer’s ability to evolve resistance to modern hormone treatments.”

Other collaborators on the study include researchers from the Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, USA.

Cancer Discovery 12 January 2021

Tags: Cancer | Men's Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)